UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Clinical trials of HIV drug resistance testing

Author
Paul E Sax, MD
Section Editor
Martin S Hirsch, MD
Deputy Editor
Jennifer Mitty, MD, MPH

INTRODUCTION

When successful, antiretroviral therapy durably controls viral replication. However, virologic suppression is not achieved in all patients and leads to virologic failure [1]. Drug resistance is a major cause and a consequence of treatment failure. Clinicians can use genotypic and phenotypic assays to assess the susceptibility of a patient's virus to many available antiretroviral agents.

The major clinical trials that assessed the relative roles of these resistance assays will be discussed here. The performance of these tests, their relative advantages and disadvantages, and recommendations regarding the use of these assays in various patient groups are discussed elsewhere. (See "Overview of HIV drug resistance testing assays" and "Drug resistance testing in the clinical management of HIV infection".)

RETROSPECTIVE STUDIES

Several retrospective studies have demonstrated a correlation between baseline HIV-1 drug resistance and subsequent virologic outcome in patients with prior treatment experience [2-13]. A subsequent analysis of 12 different studies used consistent definitions of resistance and virologic outcome in order to combine clinical trial data [14]. The primary end point for virologic failure in this analysis was plasma HIV-1 RNA concentration >400 copies/mL, 24 weeks after initiation of a salvage regimen. The analysis was significant for the following results:

Both genotypic and phenotypic testing results were important predictors of virologic failure.

The risk of virologic failure was reduced by twofold for each additional drug in the regimen, which was sensitive by genotypic testing and by two- to threefold for each additional drug identified by phenotypic testing.

          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Sat Jun 30 00:00:00 GMT 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Haubrich R, Demeter L. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr 2001; 26 Suppl 1:S51.
  2. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999; 179:1375.
  3. Rubio A, Gómez-Cano M, Puig T, et al. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load. Antivir Ther 1999; 4:45.
  4. Harrigan PR, Hertogs K, Verbiest W, et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13:1863.
  5. Lanier, E, Scott J, Steel, H, et al. Multivariate analysis of predictors of response to abacavir: comparison of prior antiretroviral therapy, baseline HIV RNA, CD4+ count, and viral resistance. Antivir Ther 1999; 4:56.
  6. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87.
  7. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13:F17.
  8. Miller V, Phillips A, Rottmann C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998; 177:1521.
  9. Zolopa AR, Shafer RW, Warford A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999; 131:813.
  10. Katzenstein, D, Bosch, R, Shafer, R, et al. Reverse transcriptase genotyping in highly experienced nucleoside sequencing and virologic response to HAART in ACTG 364. Antivir Ther 1999; 4:47.
  11. Miller V, Cozzi-Lepri A, Hertogs K, et al. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther 2000; 5:49.
  12. Para MF, Glidden DV, Coombs RW, et al. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. J Infect Dis 2000; 182:733.
  13. Clumeck N. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy. Antivir Ther 1998; 3 Suppl 4:39.
  14. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41.
  15. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195.
  16. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83.
  17. Cohen, C, Kessler, H, Hunt, S, et al. Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA3001). Antivir Ther 2000; 5:67.
  18. Melnick, D, Rosenthal, J, Cameron, M, et al. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy in heavily experienced patients. In: Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: Foundation for Retrovirology and Human Health, 2000.
  19. Vray M, Meynard JL, Dalban C, et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther 2003; 8:427.
  20. Haubrich RH, Kemper CA, Hellmann NS, et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005; 19:295.
  21. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209.
  22. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369.
  23. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14:1333.
  24. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579.
  25. Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004; 38:723.
  26. Panidou ET, Trikalinos TA, Ioannidis JP. Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS 2004; 18:2153.
  27. Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 2005; 191:1325.
  28. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175.
  29. Saracino A, Monno L, Locaputo S, et al. Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen). J Acquir Immune Defic Syndr 2004; 37:1587.
  30. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.
  31. Dunn DT, Green H, Loveday C, et al. A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators. J Acquir Immune Defic Syndr 2005; 38:553.
  32. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1 (Accessed on April 06, 2012).
  33. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.